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ABSTRACT 
Malaria tolerance is a defence strategy that limits the damage caused by Plasmodium species irrespective of pathogen burden. 
The mechanisms responsible for this, responses of these mechanisms and their impact on organs to treatment have not been 
extensively studied. Thus, in this study, serum levels of selected pro- and anti-inflammatory markers, liver and kidney function 
indices with leucocytes indices in 100 children (1-10 years) with severe falciparum malaria were determined before treatment, 
at 48 hours during treatment and 48 hours after treatment with WHO recommended dosage of artesunate/artemether-lumefantrine 
combination therapy using standard methods. Data were analysed using SPSS, differences were considered signiﬁcant at p<0.05. 
The results revealed that the serum levels of interleukin-12 (IL-12), interleukin-4 (IL-4), tumor necrosis factor-α (TNF-α), 
interferon-γ (IFN-γ), C-reactive protein (CRP), nitric oxide (NO), creatinine, albumin, total protein and conjugated bilirubin were 
not significantly changed at higher parasite densities before treatment. Only serum IL-4, CRP, total bilirubin, urea and creatinine 
levels and alanine aminotransferase activity were significantly reduced below the ranges of those with severe malaria. The results 
suggest a self-protective feed-back control, indicating tolerance, which reduced the adverse effects of the disease on kidney and 
liver functions at higher parasite densities. The results also suggest serum IL-12, IL-4, TNF-α, IFN-γ, CRP and NO levels as 
immune-protective markers for tolerance and serum IL-4 level as an effective marker for disease severity and recovery from the 
disease in children with severe malaria 
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INTRODUCTION 
 
Children are easily exposed to malaria parasite at early stage 
of life in malaria endemic regions like Nigeria (Okoli and 
Solomon, 2014). Survival from exposure to malaria leads to 
development of immunity against the pathogen (Boutlis et al., 
2005). However, the strength of the developed immunity 
depends on the number of exposure to the parasite which is 
also dependent on age (Boutlis et al., 2005).  Young children 
especially less than 5 years living in malaria endemic areas 
have fewer exposures to the parasite in comparison to older 
children or adults (Boutlis et al., 2005; Medzhitov et al., 
2012). Consequently, they have incomplete immunity against 
the parasite and can easily come down with the infection, 
especially the severe form of malaria (Penman and Gupta, 
2008). However, some children develop tolerance to the 
pathogen and are able to house the parasite burden without 
concomitant signs or symptoms such as fever; this is termed 
“anti-fever” tolerance (Boutlis et al., 2005; Medzhitov et al., 
2012). It is also termed, “anti-toxic” tolerance on the 
discovery that the immunity is against the putative 
glycosylphosphatidylinositol (GPI) toxin of P. falciparum 
(Perry et al., 2005). “Anti-fever” tolerance is more common 
in young children (Boutlis et al., 2005) as against the older 
children or adults that express “anti-parasite” immunity or 
resistance (Boutlis et al., 2006; Medzhitov et al., 2012). 
Resistance is defined as the ability to limit pathogen burden 
(Boutlis et al., 2006; Medzhitov et al., 2012). Increased serum 
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NO level has been reported as the mediator for “anti-fever” 
tolerance in children with asymptomatic malaria living in 
malaria endemic regions (Anstey et al., 1996; Jeney et al., 
2014). Tolerance has also been described in children with mild 
uncomplicated or acute symptomatic malaria in the presence 
of increasing parasite burden (Boutlis et al., 2006, Medzhitov 
et al., 2012). This is termed   “anti-severe” malaria tolerance 
(Boutlis et al., 2005). Pro- and anti-inflammatory cytokines 
are involved as mediators of “anti-severe” malaria tolerance 
(Amante and Good, 1997; Fernandes et al., 2008; Couper et 
al., 2008; Langhorne et al., 2008). 
 However, not all young children are able to express “anti-
fever” or “anti-severe” malaria tolerance because about 1-2% 
of mild uncomplicated malaria cases progress to severe 
malaria (Penman and Gupta, 2008; Tiago et al., 2011).  
Moreover, it has been documented that clinical immunity 
against malaria is short-lived and requires repetitive exposure 
to the parasite to maintain it (Boutlis et al., 2005), otherwise, 
asymptomatic malaria could progress to mild symptomatic 
uncomplicated malaria and then to severe malaria if not 
promptly diagnosed and treated (WHO, 2010). Severe malaria 
is more prevalent and lethal in children who are less than 5 
years of age and causes tissue pathology and even death 
because their acquired partial immunity which is due to their 
few exposures to the parasite causes the immune system to 
extremely respond to the pathogen it recognises without 
effectively controlling the inflammation (Penman and Gupta, 
2008).  
 Nevertheless, there are individual differences in 
inflammatory and immune responses to severe P. falciparum 
and this affects the disease outcome because either survival or 
mortality has been recorded in some children irrespective of 
the level of hyperparasitaemia (Aye Aye et al., 2016).  
Survival from the disease suggests host expression of 
tolerance to the pathogen irrespective of the 
hyperparasitaemic level (Ayres and Schneider, 2008; 
Medzhitov et al., 2012), which may limit the adverse effects 
of the increased inflammatory and immune responses on host 
tissues or organs (Ayres and Schneider, 2008; Medzhitov et 
al., 2012) before effective treatment is administered. Thus, 
studying the responses of inflammatory markers in severe 
malaria, their effects on selected organs and their responses to 
treatment may give a better understanding of the underlying 
mechanisms responsible for either positive or negative 
outcomes observed after treatment of severe malaria and may 
also help in identifying new markers for disease tolerance, 
disease severity and recovery from the disease. Thus, this 
study was carried out to evaluate the responses of selected 
inflammatory, kidney and liver function markers in serum of 
Nigerian children with severe falciparum malaria to treatment 
with artesunate/artemether-lumefantrine combination therapy. 
 
MATERIALS AND METHODS 
 
Rapid diagnostic test (RDT) kits for hepatitis B and HIV 
screening were obtained from Standard Diagnostics, Korea. 
Unless otherwise stated, all the reagents used for this study 
were of analytical grade and were prepared in all glass-
distilled water. 
 
Study population: One hundred children with severe malaria 
aged 1 to 10 years, treated at the Paediatrics wards of Jos 
University Teaching Hospital (JUTH), a reference tertiary 
hospital in Jos, North-Central Nigeria, were recruited for this 
study from 28th April 2014 to 15th February, 2016.  
Children who met the study’s inclusion criteria were recruited 
consecutively for the study. The inclusion criteria were: (i) 
assent of the child and parent/caregiver’s consent; (ii) children 
aged 1 to 10 years clinically presenting with severe malaria 
without any other ailment as diagnosed by the paediatrician 
(severe malaria was diagnosed as the presence of one or more 
symptoms of malaria complications e.g anaemia, respiratory 
distress, jaundice etc and detection of malaria parasite 
(hyperparasitaemia)/product in the patient’s blood); (iii) 
children with confirmed hyperparasitaemia using microscopy; 
(iv) children confirmed by laboratory tests as presenting with 
only severe malaria after excluding other disease conditions 
such as septicaemia, helminthiasis, typhoid, shigellosis, 
glucose-6-phosphate dehydrogenase deficiency (G6PDD), 
sickle cell disease, human immune-deficiency virus (HIV) and 
hepatitis B; (v) children on admission in the hospital using 
mosquito bed-net; (vi) children on artesunate/artemether-
lumefantrine combination therapy; and (vii) children that 
recovered and were discharged on the 7th day of admission.  
 
Ethical Approval: This study was carried out in line with the 
ethics guiding research undertakings on human subjects as 
approved by the ethical committees of University of Ilorin 
(reference No. UERC/ASN/2014/013) and Jos University 
Teaching Hospital (reference No. 
JUTH/DCS/ADM/127/XIX/5933). In addition, informed 
consents of the children’s parents or caregivers were obtained 
before enrolment after due explanation of the aims and 
procedures of the project.  
 
Study Design: This was a prospective longitudinal hospital-
based study. 
 
Administration of drugs: The children were given 2.4 mg/kg 
body weight of artesunate intravenously at 0 hour and then 1.2 
mg/kg body weight at 12, 24 and 48 hours (if the patient was 
able to swallow, the daily dose was given orally) by the 
paediatricians and nurses. This was followed by oral 
administration of artemether-lumefantrine combination 
therapy at doses of 5 to 24 mg/kg body weight of artemether 
and 29 to 144 mg/kg body weight of lumefantrine for 3 days 
as fixed doses (WHO, 2015). 
 
Sample collection and laboratory analysis: After clinical 
assessment, 5 ml of blood was aseptically collected from the 
ante-cubital vein of the children using sterile needle and 
syringe. This was done before initiation of treatment on the 
day of admission (day 0), then 48 hour after initiation of 
treatment (day 2) (Watt et al., 1992). Another sample was 
collected 48 hours after the last dose of the combination 
therapy i.e 7th day of initiation of treatment (CATMAT, 2000).  
Three millilitres (3 ml) of the blood was dispensed into EDTA 
tube for screening tests for exclusion of other abnormalities, 
malaria parasite detection and haematological tests. Screening 
tests for exclusion of other abnormalities carried out include:  
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haemoglobin genotype for exclusion of sickle cell disease 
using electrophoresis as described by Roberts and Williams 
(2003), glucose-6 phosphate dehydrogenase (G6PD) test for 
exclusion of G6PD deficiency using the meth-haemoglobin 
qualitative method described by Brewer et al. (1962), hepatitis 
B surface antigen test for exclusion of viral hepatitis using 
lateral flow technique (rapid diagnostic test (RDT) and blood 
culture for exclusion of septicaemia by direct aseptic injection 
of the blood into brain-heart infusion broth and thioglycollate 
broth (at 1:20 dilution) as described by Cheesbrough (2005). 
The remaining 2 ml of the blood was dispensed into screw-
caped plain sample tube for serum preparation. It was allowed 
to clot and retract at room temperature (22-27 oC) for about 20 
minutes. The serum was separated after centrifuging at 3000 
revolutions per minute (rpm) for 5 minutes in a clinical bench 
top centrifuge (MSE minor, England) using pasteur pipette 
into a pre-cleaned, dried, metal and steroid free cryo-vials and 
was used for HIV screening using the 
immunochromatographic technique (RDT) and biochemical 
analysis. Tests were carried out in duplicate tubes. 
Stool sample was collected once into a transparent stool 
container from the children for exclusion of helminthiasis and 
pathological enteric bacterial infection by stool microscopy 
and culture tests using normal saline method for microscopy 
and Selenite-F and dextrose-citrate agar for culture as 
described by Cheesbrough (2005). 
 
Malaria diagnosis: Malaria parasite detection was carried out 
by microscopy using Giemsa stained duplicate thick and thin 
slides (Cheesbrough, 2010). The duplicate slides were blindly 
read by an expert microscopist who is involved in the study; 
this served as the internal quality control. The slides were also 
read by another expert microscopist who was not involved in 
the study (independent reader); this served as the external 
quality control. The degree of variation in the results was 
determined and statistical analyzed. Malaria diagnosis was 
based on identification of asexual stages of Plasmodium 
species in the thick blood smears. Film was reported as 
‘malaria parasite not seen’ i.e. negative after examining about 
100 fields. Thin films were used to identify species and stages 
of the parasite. 
 Malaria parasite density was determined as the number of 
parasites/µl of blood (thick film method) relative to respective 
patient’s total white blood cell count (WHO, 2007). 
Hyperparasitaemia in children was defined as parasite count 
of >200 x 103 parasites/µl (Maina et al., 2010). 
 Children with severe malaria were grouped based on age.  
Parasite densities before treatment (day 0) were grouped into 
mild hyperparasitaemia (201 to 300 x 103 parasites/µl), 
moderate hyperparasitaemia (301 to 500 x103 parasites/µl) and 
marked hyperparasitaemia (501 to 800 x103 parasites/µl).  
Parasite densities during treatment (day 2) were grouped into 
malaria parasite not seen (treated malaria negative, 0.0 x103 
parasites/µl), low parasitaemia (1 to 100 x103 parasites/µl) and 
moderate parasitaemia (101 to 200 x103 parasites/µl) while 
parasite densities after treatment (day 7) were grouped into 
malaria parasite not seen (treated malaria negative, 0.0 x103 
parasites/µl) and low parasitaemia (1 to 100 x103 parasites/µl). 
  
Haematological analysis: Total and differential leucocytes 
counts were determined manually (WHO, 1991). 
 
Biochemical assays: Serum levels of tumour necrosis factor- 
α (TNF-α), interferon- γ (IFN-γ), interleukin-12 (IL-12), IL-4 
and IL-10 were determined using standalone enzyme linked 
immunosorbent assay (ELISA) as described by Natsuko et al. 
(2011).  C-reactive protein (CRP) and nitric oxide (NO) 
concentrations were determined using the methods described 
by Black et al. (2004) and Griess (1978) respectively. Alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) 
and alkaline phosphatase (ALP) activities and the 
concetrations of total protein and albumin in the serum were 
determined using the methods described by Friedman et al. 
(2003). Total and conjugated bilirubin concentrations in the 
serum were determined using the method of Jendrassik and 
Grof (1938).  Serum urea and creatinine concentrations were 
determined using the methods described by Amin et al. 
(2014).  
 
Statistical Analysis: Results are expressed as means ± 
standard error of the mean (S.E.M.). Data were analysed using 
one-way ANOVA, followed by Duncan’s multiple range test 
and the level of their relationships in children with severe 
malaria before treatment (day 0), 48 hours after initiation of 
treatment (day 2) and 48 hours after treatment (day 7) were 
determined using Pearson correlation. Differences were 
considered significant at P<0.05 when compared among the 
different parasite density ranges 
 
RESULTS 
 
Parasite density by number and age of children with severe 
malaria before, during and after treatment. The parasitaemia 
in children with severe malaria before treatment (day 0), 48 
hours after initiation of treatment (day 2) and 48 hours after 
treatment (day 7) are shown in Table 1. The results revealed 
that artesunate/artemether-lumefantrine combination therapy 
caused significant reduction (p<0.05) in parasite density on 
days 2 and 7 compared to those of day 0 (Table 1).   
 
Responses of selected white blood cell indices to change in 
parasite density in children with severe malaria before, 
during and after treatment : Responses of total white blood 
cell, absolute neutrophil, absolute lymphocyte, absolute 
monocyte and absolute eosinophil counts to change in parasite 
density in children with severe malaria before treatment (day 
0), 48 hours of treatment (day 2) and 48 hours after treatment 
(day 7) are shown in Figure 1. There was relatively no 
significant change (p>0.05) in the white blood cell indices 
with increase in parasite density from 201 to 800 x103 
parasites/µl before treatment; indicating that they are non-
markers of disease severity (Figs. 1 A-E). Blood lymphocyte 
counts showed a strong significant correlation (r = .012) with 
parasite density. Total white blood cell, neutrophil, monocyte 
and eosinophil counts showed weak significant positive 
correlation (r = .343, r = .378, r =.306, r = .189 respectively) 
with parasitaemia (Figs. 1A-E).  
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Responses of selected inflammatory markers in serum to 
change in parasite density in children with severe malaria 
before, during and after treatment 
 
There was significant increase (p<0.05) in serum levels of 
TNF-α, IFN-γ, IL-12, IL-4 and CRP with significant rise 
(p<0.05) in parasite density from 201 to 400 x 103 /µl (mild to 
moderate hyperparasitaemia) with no significant change 
(p>0.05) in their levels with further significant increase 
(p<0.05) in parasite density from 401 to 800 x 103 /µl (501 to 
800 x103/µl for IL-4, CRP) (marked hyperparasitaemia) 
before treatment (Figs. 2A-F). The levels decreased 
significantly (p<0.05) during and after treatment (Figs. 2A-F).  
Serum TNF-α, IFN-γ, IL-12, IL-4 and CRP concentrations 
showed a significant positive correlation (r=.593; r =.441; r = 
.574; r= .844; r = .803 respectively; p<0.05) with parasitaemia, 
but IL-10 had a weak non-significant negative correlation (r = 
- .079; p >0.05) (Fig. 2A-F). 
 
Response of serum nitric oxide to change in parasite 
density in children with severe malaria before, during and 
after treatment 
The results revealed that there was a steady decrease in serum 
NO level with increase in parasite density from 201 to 500 
x103 parasites/µl (mild to moderate hyperparasitaemia) which 
was significant (p<0.05) at parasite density of  501- 600 x 103 
parasites/µl on day 0 compared to those of days 2 and 7 (Fig. 
3). Following a further increase in parasite density to 501 to 
600 x103 parasites/µl, there was significant increase (p<0.05) 
in serum NO concentration to the range of those of days 2 and 
7. With further significant increase (p<0.05) in parasite 
density from 601 to 800 x103 parasites/µl (marked 
hyperparasitaemia), there was no significant change (p>0.05) 
in serum NO concentration compared to those of day 2 (Fig. 
3). The level increased significantly (p<0.05) during and after 
treatment and correlated negatively (r= -.510; p<0.05) with 
parasitaemia and disease severity (Fig. 3). 
 
 
 
Table 1: 
Parasite densities by number and age of children with severe malaria before, during and after treatment with 
artesunate/artemether-lumefantrine combination therapy 
Range of parasite density 
 
Parasite density 
Mean ± SD 
Number of 
Children 
Age (years) 
Mean ± SD 
Age range (years) 
Day 0 (before treatment) 
 
Mild hyperparasitaemia 
    
201-300 (x103 parasites/µl) 
Moderate hyperparasitaemia 
237.64 ± 27.74 33 (33%) 4.63 ± 2.44 1.60 – 10.00 
301-400 (x103 parasites/µl) 361.69 ± 34.42 16 (16%) 2.53 ± 1.68 1.00 – 6.00 
401-500 (x103 parasites/µl) 
Marked hyperparasitaemia 
462.35 ± 22.03 17 (17%) 4.74 ± 2.11 1.60 – 10.00 
501-600 (x103 parasites/µl) 532.0 ± 21.99 14 (14%) 3.89 ± 3.36 1.00 – 10.00 
601-700 (x103 parasites/µl) 640.0 ± 14.14 2 (2%) 2.70 ± 0.00 2.70 – 2.700 
701-800 (x103 parasites/µl) 793.89 ± 7.96 18 (18%) 4.21 ± 2.63 1.00 – 10.00 
 
Day 2 (48 hours of treatment) 
 
MP not seen (treated MP- negative) 
    
0.0 (x103 parasites/µl) ) 
Low parasitaemia 
0.00 7 (7%) 4.00 ± 2.97 2.00 – 10.00 
01-100 (x103 parasites/µl) 
Moderate parasitaemia 
83.33 ± 12.81 18 (18%) 5.38 ± 2.51 2.80 – 10.00 
101-200 (x103 parasites/µl) 167.61 ± 20.41 75 (75%) 3.80 ± 2.31 1.00 – 10.00 
 
Day 7 (48 hours after treatment) 
 
MP not seen (treated MP- negative) 
    
0.0 (x103 parasites/µl)  
Low parasitaemia 
0.00 93 (93%) 3.93 ± 2.45 1.00 – 10.00 
01-100 (x103 parasites/µl) 85.0 ± 14.43 7 (7%) 6.29 ± 2.69 1.00 – 10.00 
MP = malaria parasite 
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Figure 1:  
Responses of white blood cell indices to change in 
parasite density in children with severe malaria 
before, during and after treatment with 
artesunate/artemether-lumefantrine combination 
therapy.  
A -Total white blood cell count; B - absolute 
neutrophil count; C - absolute lymphocyte count; D - 
absolute monocyte count; E - absolute eosinophil 
count. Values are means ± S.E.M of 100 children; 
Day 0 - before treatment, Day 2 - 48 hours of 
treatment; Day 7 - 48 hours after treatment. Values 
with different superscripts for each parameter are 
significantly different (p<0.05). 
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Figure 2: 
Responses of selected inflammatory markers to change in parasite density in children with severe malaria before, 
during and after treatment with artesunate/artemether-lumefantrine combination therapy.  
A –Tumor necrosis factor; B – interferon gamma; C – interleukin-12; D – interleukin-4; E – interleukin 10; F – C-reactive 
protein. Values are means ± S.E.M of 100 children; Day 0 - before treatment, Day 2 - 48 hours of treatment; Day 7 - 48 hours 
after treatment. Values with different superscripts for each parameter are significantly different (p<0.05). 
 
 
  
Figure 3:  
Response of serum nitric oxide to change in parasite 
density in children with severe malaria before, during and 
after treatment with artesunate/artemether-lumefantrine 
combination therapy.  
Values are means ± S.E.M of 100 children; Day 0 - before 
treatment, Day 2 - 48 hours of treatment; Day 7 - 48 hours 
after treatment. Values with different superscripts are 
significantly different (p<0.05). 
 
Responses of some renal function indices in serum to 
change in parasite density in children with severe malaria 
before, during and after treatment: The result revealed that 
serum urea concentration showed multiphasic non-specific 
variations with significant rise (p<0.05) in parasite density 
from 201 to 800 x103 parasites/µl before treatment (Fig. 4A). 
Serum creatinine level was significantly increased (p<0.05) 
with significant rise (p<0.05) in parasite density from 301 to 
500 x103 parasites/µl (mild to moderate hyperparasitaemia), 
which was not significantly changed (p>0.05) with further 
significant increase (p<0.05) in parasite densities from 601 - 
800 x103 parasites/µl (marked hyperparasitaemia) day 0 (Fig. 
4B). Serum creatinine and urea levels decreased significantly 
(p<0.05) with treatment and significantly correlated (r=.555; 
r= .552 respectively) with parasitaemia and disease severity 
(Fig. 4A-B).  
 
Responses of some enzymic liver function indices in the 
serum of children with severe malaria to change in 
parasite density before, during and after treatment 
There was significant increase (p<0.05) in serum ALT activity 
with significant rise (p<0.05) in parasite density from 301 to 
800 x103parasites/µl to those days 2 and 7 (Fig. 5A). There 
was significant increase (p<0.05) in serum AST activity with  
increase in parasite densities from 301 to 600 x103 parasites/µl 
compared to those of day 7 and from 601 – 800 x103 
parasites/µl compared to those of day 2 (Fig. 5B). There was 
no significant change (p>0.05) in ALP activity with 
significant increase (p<0.05) in parasite density from 201 to 
800 x103 parasites/µl on day 0 compared those of days 2 and 
7 (Fig. 5C). Serum ALT and AST activities correlated with 
parasitaemia and disease severity (r = .774; r = .661 
respectively) (Figs. 5A-B), but serum ALP activity was not 
significantly changed (p>0.05) during and after treatment and 
showed a non-significant negative correlation (r = -.042; 
p>0.05) with parasitaemia and malaria severity (Fig. 5C). 
 
 
 
Figure 4: 
Responses of selected kidney function indices in the serum to change in parasite density in children with severe malaria 
before, during and after treatment with artesunate/artemether-lumefantrine combination therapy. A – Urea 
concentration; B – Creatinine concentration; Values are means ± S.E.M of 100 children; Day 0 - before treatment, Day 2 - 48 
hours of treatment; Day 7 - 48 hours after treatment. Values with different superscripts for each parameter are significantly 
different (p<0.05). 
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Figure 5: 
Responses of selected enzymic liver function indices to change in parasite density in children with severe malaria before, 
during and after treatment with artesunate/artemether-lumefantrine combination therapy.  
Values are means ± S.E.M of 100 children; Day 0 - before treatment, Day 2 - 48 hours of treatment; Day 7 - 48 hours after 
treatment. Values with different superscripts are significantly different (p<0.05). 
 
 
 
Figure 6:  
Responses of selected non-enzymic liver function indices to change in parasite density in children with severe malaria 
before, during and after treatment with artesunate/artemether-lumefantrine combination therapy.  
Values are means ± S.E.M of 100 children; Day 0 - before treatment, Day 2 - 48 hours of treatment; Day 7 - 48 hours after 
treatment. Values with different superscripts are significantly different (p<0.05); 
A - Serum albumin concentration; B – Serum total protein concentration (TB); C – Serum total bilirubin concentration; and D - 
Serum conjugated bilirubin concentration (CB) 
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Responses of some serum non-enzymic markers of liver 
function to change in parasite density in children with 
severe malaria before, during and after treatment 
There was no significant change (p>0.05) in serum albumin 
level with significant rise (p<0.05) in parasite density from 
201 to 400 x103 parasites/µl (mild to moderate 
hyperparasitaemia) on day 0 compared to those of days 2 and 
7, but serum total protein concentration was not significantly 
changed (p>0.05) at all parasite densities on day 0 compared 
to those of day 7 (Fig. 6). Serum albumin and total protein 
levels were reduced significantly (p<0.05) on day 0 compared 
to those of day 2 at parasite densities of 501 – 800 x103 
parasites/µl) (Figs 6A and B). They correlated negatively with 
parasitaemia and disease severity (r= -.450; r= -.399 
respectively; p<0.05) (Figs. 6A and B). 
 There was significant increase (p<0.05) in total bilirubin 
level (TB) with significant increase (p<0.05) in parasite 
density from 301 to 800 x103 parasites/µl on day 0 compared 
to those of days 2 and 7 (Fig. 6C). Serum conjugated bilirubin 
concentration (CB) was significantly increased (p<0.05) at 
parasite density of 301 to 400 x103 parasites/µl (moderate 
hyperparasitaemia), with no significant change (p>0.05) at 
other parasite densities compared to those of days 2 and 7. 
Serum TB and CB correlated with parasitaemia and disease 
severity (r=.691; r=.196 respectively; p<0.05) (Figs. 6C and 
D). 
 
 
DISCUSSION 
 
The clinical presentations in children with severe malaria 
include anaemia, jaundice, respiratory distress and prostration 
(Okoli et al., 2017). Various physiological mechanisms are 
responsible for these, such as inflammation, multi-organ 
complications etc. In this study, the possible modulation of the 
markers of inflammation, liver and kidney functions in 
children with severe malaria treated with 
artesunate/artemether-lumefantrine combination therapy was 
evaluated, with the aim of getting more reliable markers for 
monitoring disease severity and recovery during treatment. 
The treatment ameliorated the adverse effects which 
hyperparasitaemia and the concomitant increased 
inflammatory and immune responses would have exerted on 
various organs, which in turn could have led to more advanced 
complications and death.  
 Host’s defensive capacity affects the outcome of severe 
malaria (Ayres and Schneider, 2008). Tolerance, host’s 
defensive strategy, does not affect the pathogen burden or 
density but reduces tissue damage and other pathological 
effects of disease caused by the pathogen or immune response 
(Medzhitov et al., 2012). Host expression of tolerance as a 
means of preventing symptomatic or severe malaria even in 
the presence of the pathogen has been reported (Boutlis et al., 
2006; Medzhitov et al., 2012). However, the mechanisms 
underlying host expression of tolerance in severe P. 
falciparum malaria as a means of limiting the damaging 
effects of increasing parasite densities on host tissues or 
organs has not been fully elucidated.   
  
Severe malaria alters haematological indices (Bidaki and 
Dalimi, 2003). White blood cells are known to be involved in 
immune response (Pilger et al., 2011). From this study, the 
pattern of regulation of white blood cell indices did not 
connote them as markers for tolerance. This is in line with 
already established fact that white blood cells are not involved 
in expression of tolerance (Boutlis et al., 2006; Medzhitov et 
al., 2012). Total white blood cell, neutrophil, monocyte and 
eosinophil counts exhibited weak positive correlation with 
parasitaemia. Thus, they may not be good markers for disease 
severity and monitoring recovery during treatment because 
their values before, during and after treatment were not 
significantly different.  
 Modulatory effects of Plasmodium infection on the 
concentrations of pro- and anti-inflammatory markers in the 
serum have been well documented (Nmorsi et al., 2010; 
Prakash et al., 2006). The results of this study, revealed that 
the serum levels of TNF-α, IFN-γ, IL-12, IL-4, and CRP 
correlated positively with parasite density and disease 
severity, NO correlated negatively and IL-10 showed a non-
significant negative correlation. However, serum TNF-α, IFN-
γ, IL-12, CRP and NO levels may not be good markers for 
disease severity because they were not significantly changed 
at higher parasite densities, possibly due to self-protective 
feedback control (Ejezie and Ezedinachi, 1992). The serum 
IL-4 levels of the categories of parasite densities used in this 
study were significantly different from each other, suggesting 
that serum IL-4 level may be a good marker for determining 
disease severity. Serum TNF-α, IFN-γ, IL-12 and NO levels 
may not be good markers for monitoring recovery because 
they were not significantly changed before, during and after 
treatment. However, serum IL-4 and CRP levels may be 
effective markers for monitoring recovery from the disease 
because they were significantly reduced during and after 
treatment compared to their values before treatment. 
 Elevated serum TNF-α, IL-12 and IFN-γ levels have been 
reported severally in severe malaria (Nmorsi et al., 2010; 
Prakash et al., 2006). TNF-α and IFN-γ are T1 
proinflammatory cytokines (Nmorsi et al., 2010; Prakash et 
al., 2006).  IL-12 is also pro-inflammatory cytokine, required 
for the production of protective immunoglobulin IgG2a (Su 
and Stevenson, 2002).  From this study, elevated serum TNF- 
α, IFN-γ and IL-12 levels showed a self-protective feedback 
control (Ejezie and Ezedinachi, 1992) before treatment in 
response to increasing parasite density (Dubey et al., 1999; 
Tiago et al., 2011). Tiago et al. (2011) found that the 
expression of cytokine genes, which is related to serum levels 
of cytokines, can be modulated by the number of parasites.  
This curtails damage on tissues or organs due to 
overproduction of these pro-inflammatory cytokines (Ayres 
and Schneider, 2008; Medzhitov et al., 2012). This suggests 
that TNF- α, IFN-γ and IL-12 are markers for tolerance (Ayres 
and Schneider, 2008; Medzhitov et al., 2012), which is 
expressed in these children with severe falciparum malaria in 
this malaria endemic region. Expression of tolerance via a 
self-protective control of elevated serum TNF-α could be due 
to inhibition of soluble TNF-α receptor, as it has been reported 
that at high TNF-α concentrations, the soluble TNF-α 
receptors compete with TNF-α for binding with cellular 
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receptors particularly membrane-bound TNF-α (Opal et al., 
1991), thereby inhibiting TNF-α bioactivity; this, by 
implication, results in negative feedback control of serum 
TNF-α (Overbeek and Veringa 1991; Ayres and Schneider, 
2008). The mechanism for the increased serum IFN-γ level in 
this immunological response could be related to the finding 
that Th1 effector cells can exert negative feedback control to 
regulate themselves (do Rosario, 2012).  Also, the roles of pro-
inflammatory cytokines such as TNF-α and IFN-γ and the 
anti-inflammatory cytokine, IL-4, in iron delocalization 
pathway lead to malaria anaemia (Garcia, 2010; Heinrich et 
al., 2003) and reduced availability of iron to the parasite which 
reduces the parasite  pathogenecity and confers tolerance to 
malaria (Gozzelino et al., 2012).  
 Elevated serum IL-4 and CRP levels in severe malaria 
have been reported (Nmorsi et al., 2010; Streetz et al., 2003; 
Kulkarni et al., 2003). IL-4 is a regulator of the heavy chain 
class switch from IgM to IgG1, IgG3 and IgE in B cells (Curfs 
et al., 1990; Calissano et al. 2003). C-reactive protein is a 
peitrophic acute phase protein synthesised by hepatocytes 
(Tilg et al., 1993; Streetz et al., 2003). In this study, elevated 
serum IL-4 and CRP levels showed a self-protective feedback 
control (Ejezie and Ezedinachi, 1992) before treatment in 
response to increasing parasite density (Dubey et al., 1999; 
Ejezie and Ezedinachi, 1992), suggesting tolerance. This 
corroborates earlier report by Medina et al. (2011) that serum 
levels of IL-4 may increase or decrease significantly over the 
course of infection. Moreover, Gennaro (2000) reported that 
cytokines can suppress their own effect by feedback 
inhibition. Thus, IL-4 and CRP are markers for tolerance 
(Ayres and Schneider, 2008; Medzhitov et al., 2012).  
 IL-10 is an anti-inflammatory Th2-type cytokine (Tiago 
et al., 2011). Decreased serum IL-10 level has been shown to 
have a non-significant or weak negative correlation with 
parasite density (Tiago et al., (2011). In this study, it was 
observed that the decreased serum IL-10 level did not express 
a self-protective feedback control (Ejezie and Ezedinachi, 
1992) with increasing parasite density (Dubey et al., 1999) 
because there was no significant change in its concentration at 
various parasite densities. Thus, IL-10 is not a marker for 
tolerance. This suggests that the mechanisms of tolerance for 
the disease expressed by these children did not involve 
reduction in the serum level of this anti-inflammatory cytokine 
(Ejezie and Ezedinachi, 1992).  
 Decreased serum NO level has been reported to exist in 
patients with severe malaria (Weiberg et al., 2008). NO is a 
final effector molecule; it is a highly diffusible, lipid-soluble, 
free radical that has been identified to mediate in malaria 
tolerance (Anstey et al., 1996; Jeney et al., 2014). In this 
study, the reduced serum NO level suggests a self-protective 
feed-back control (Ejezie and Ezedinachi, 1992) with 
increasing parasite density before treatment. This suggests 
that one of the mechanisms of tolerance for the disease in these 
children involves reduction of serum NO level thereby 
limiting the damaging effect on organs (Ayres and Schneider, 
2008; Medzhitov et al., 2012). This finding corroborates 
earlier reports by Chung et al. (1980) and Stefano and 
Magazine (2001) that NO may be a self-regulatory molecule. 
In addition, suppressed NO synthesis and overproduction of 
TNF-α have been associated with cerebral malaria (Weiberg 
et al. 2008; Grau et al., 1989). However, the fact that none of 
our subjects in this study had cerebral malaria (Okoli et al., 
2017) despite decreased serum NO and increased TNF-α 
levels further suggest the conferment of tolerance; otherwise, 
this possibly, could have escalated to cerebral malaria and, 
possibly, death (Ayres and Schneider, 2008; Medzhitov et al., 
2012).  Severe malaria is associated with 
dysregulated inflammatory and immune responses which can 
result in liver damage (Gozzelino and Soares, 2011), causing 
alteration in the serum levels or activities of liver function 
markers (Kochar et al., 2003; Nautiyal et al., 2005). Elevated 
serum activities of ALT and AST and serum concentrations of 
total bilirubin and conjugated bilirubin concentrations are 
associated with severe malaria (Kochar et al., 2003; Nautiyal 
et al., 2005), which indicate liver injury, because, the invasion 
of hepatocytes by parasites causes compromise of the cell 
membrane integrity (the marker of which is ALP activity) and 
conjugating ability of the liver (Adegbesan et al., 2014; Ki-
Soo, 2013).  Hepatocytes contain characteristic enzymes 
including ALP, ALT and AST which are released into the 
blood only when these cells are damaged (Ki-Soo, 2013).  The 
results revealed that serum ALP activity was not significantly 
changed during and after treatment compared to the value 
before treatment suggesting that it may not be useful for 
monitoring disease severity neither for monitoring recovery 
during and after treatment. AST and ALT activities positively 
correlated with parasite density, though they were not 
significantly changed over a range of parasite densities. This 
suggests that they may not be effective markers for disease 
severity. However, serum ALT activity was significantly 
reduced during and after treatment compared to the value 
before treatment, suggesting that it may be a good marker for 
monitoring recovery during treatment.  
 From this study, elevated serum ALP, ALT and AST 
activities did not show any self-protective feedback 
modulation with increasing parasite density, suggesting that 
maintenance of integrity of hepatocyte membrane is not one 
of the mechanisms of conferring tolerance in these children 
(Ayres and Schneider, 2008; Medzhitov et al., 2012). This 
finding corroborates the reports of Wunderlich et al. (2014) 
who stated that blood stage malaria causes injury to the liver 
evidenced with elevated  ALP, ALT and AST activities and 
that there are liver injuries mainly produced by malaria-
induced overreactions of the liver-inherent immune system. 
However, our findings differ from that of Vlahopoulos et al. 
(2015) who reported that normal tissue integrity is preserved 
by feedback interactions between diverse cell types mediated 
by adhesion molecules and secreted cytokines. 
Decreased serum levels of albumin and total protein, which 
are markers of liver synthetic ability (Ki-Soo, 2013), are 
associated with severe malaria (Ki-Soo, 2013). In this study, 
decreased serum albumin and total protein levels showed a 
self-protective feedback control with increasing parasite 
density and increased inflammatory and immune responses. 
This suggests that one of the mechanisms involved in 
conferment of tolerance was by reduction in the synthetic 
ability of the liver (Ayres and Schneider, 2008; Medzhitov et 
al., 2012). In this study, serum albumin and total protein 
concentrations weakly correlated negatively with parasitaemia 
but were not significantly changed before, during and after 
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treatment, suggesting that these parameters may not be good 
markers of disease severity neither for monitoring recovery 
during treatment.  
  Also, severe malaria is associated with elevated serum 
total bilirubin and conjugated bilirubin (a marker of liver 
conjugating ability) levels (Adegbesan et al., 2014; Ki-Soo 
Kang, 2013). In this study, elevated serum total bilirubin level 
and a latter reduction in serum conjugated bilirubin level 
showed a self-protective feedback control with increasing 
parasite density and increased inflammatory responses before 
treatment. This implies that tolerance was conferred by 
increasing conjugating and secretory activities of liver cells 
(Ayres and Schneider, 2008; Medzhitov et al., 2012; Medeiros 
et al., 2013; Brugat et al., 2014). This also suggests that  
elevated bilirubin clinically presented as jaundice by the 
children (Okoli et al., 2017) was because of excessive 
haemolysis that resulted in hepatomegaly due to liver overload 
(Mackowiak, 2000) and not necessarily because of severe 
liver damage as liver conjugating ability was relatively 
preserved (Ayres and Schneider, 2008; Medzhitov et al., 
2012). This agrees with the report of Wunderlich et al. (2014) 
who reported that the liver-inherent immune system has the 
capacity to generate tolerance. The results revealed that serum 
total bilirubin and conjugated bilirubin concentrations 
correlated positively with parasitaemia; however, they may 
not be effective markers of disease severity because they were 
not significantly changed with increasing parasite density. 
Also, only the total bilirubin concentration was significantly 
reduced during and after treatment compared to the values 
before treatment, suggesting that the total bilirubin 
concentration may be good marker for monitoring recovery 
during treatment. However, serum conjugated bilirubin level 
may not be a good marker for monitoring disease severity 
because there was generally no significant change in its values 
before, during and after treatment. The restoration of these 
liver functions and resolution of the serum levels of these 
markers after treatment corroborates earlier report of Sumanta 
et al. (2014) who stated that the liver efficiently restores 
function after damage induced during malarial infection once 
the parasites are cleared from the blood. Moreover, it has been 
reported that the liver also possesses the capability for fast 
regeneration after damage and this capability also involves T 
cell-mediation via cytokine repair mechanisms of the liver-
inherent immune system (Mastelic et al., 2012).  
 Elevated serum urea, a marker of renal function is 
associated with severe malaria (Ekeanyanwu and Akpoilih, 
2010). In the present study, the pattern of regulation of 
elevated serum urea in children with severe malaria did not 
show a self-protective feedback control (Ejezie and 
Ezedinachi, 1992). On the other hand, elevated serum 
creatinine, a more reliable marker for renal function (Gowda 
et al., 2010), showed a self-protective feedback control (Ejezie 
and Ezedinachi, 1992) with increasing parasite density. This 
suggests that maintenance of glomerular filtration in the 
kidney despite increasing parasite density and increased 
inflammatory response (Ayres and Schneider, 2008; 
Medzhitov et al., 2012) may be one of the mechanisms of 
conferring tolerance. These findings corroborate our earlier 
report that only few children with severe malaria exhibited 
dysuria or oliguria (Okoli et al., 2017) without any severe 
renal damage. Ramosa et al (2019) have also reported the 
establishment of tolerance to malaria through a tissue damage-
control mechanism that operates specifically in renal proximal 
tubule epithelial cells (RPTEC). As labile heme (which has the 
potential of causing membrane damage) accumulates in 
plasma and urine during the blood stage of Plasmodium 
infection, it is detoxified in RPTEC by heme oxygenase-1 and 
ferritin H chain, thereby preventing the development of acute 
kidney injury. The restoration of renal functions and 
resolution of the serum levels of the markers after treatment 
with antimalarial drugs (without any renal disease therapy) 
still confirmed that there was no severe renal damage. The 
results of this study established a weak positive correlation 
between serum urea and creatinine concentrations and parasite 
density, with no significant change at higher parasite densities. 
This suggests that they may not be good indicators of disease 
severity. However, there was significant reduction in these 
parameters during and after the treatment compared to the 
values before treatment, especially at higher parasite densities. 
This suggests that serum urea and creatinine concentrations 
may be good markers for monitoring recovery during 
treatment.  
 In conclusion, the results of this study suggests that 
serum TNF-α, IFN-γ, IL-12, IL-4, CRP and NO are immuno-
protective markers for tolerance, indicating that the immune 
system of children in this malaria endemic region expresses 
tolerance even in severe  falciparum malaria. This prevented 
fatal liver and kidney damage with increasing parasite 
density, thereby preventing possible mortality before 
treatment and resulting in 100% recovery in children after 
treatment. The results also suggest that the effective markers 
of monitoring recovery during treatment are serum IL-4, 
CRP, total bilirubin, urea, creatinine levels and ALT activity 
and only serum IL-4 level may be used for determining 
disease severity. Thus, serum IL-4 level may be used as an 
effective marker for disease tolerance, disease severity and 
recovery from the disease during treatment. 
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